Alnylam Pharmaceuticals, Inc. (ALNY)

Market Cap	32.44B
Revenue (ttm)	2.25B
Net Income (ttm)	-278.16M
Shares Out	129.46M
EPS (ttm)	-2.18
PE Ratio	n/a
Forward PE	472.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	542,016
Open	253.70
Previous Close	251.00
Day's Range	247.02 - 253.70
52-Week Range	141.98 - 304.39
Beta	0.35
Analysts	Buy
Price Target	305.86 (+22.06%)
Earnings Date	Feb 13, 2025

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2004
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: ALNY
• Website: https://www.alnylam.com

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Analyst Forecast

According to 23 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $305.86, which is an increase of 22.06% from the latest price.

Price Target

$305.86

(22.06% upside)

Analyst Consensus: Buy